A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor

Archives of General Psychiatry
J J MannR P Brown

Abstract

Monoamine oxidase (MAO) inhibitors are effective antidepressants whose use is limited because of unwanted side effects and the possibility of a tyramine-induced hypertensive crisis (cheese reaction). (-)-Deprenyl (the official nonproprietary name for this substance is selegiline), a selective MAO type B inhibitor, may be safer and have fewer side effects, but its antidepressant efficacy is uncertain. A double-blind placebo-controlled study was carried out in depressed outpatients who were treated with (-)-deprenyl in an MAO type B selective dose range and at a higher nonselective dose range. (-)-Deprenyl did not have a statistically significant antidepressant effect after three weeks of treatment at doses of 10 mg/d. However, after six weeks and at higher doses (averaging about 30 mg/d for the second three weeks), (-)-deprenyl was superior to placebo in antidepressant effect with a positive response rate of 50% vs 13.6% and with a 41% reduction in the Hamilton Depression Rating Scale mean score vs 10% in the placebo-treated group. No hypertensive crises were seen. The rate of occurrence of side effects with (-)-deprenyl was no greater than with placebo. It was concluded that (-)-deprenyl is an effective antidepressant in a dose...Continue Reading

Citations

Mar 4, 1995·Lancet·M G Livingston
May 20, 1999·Journal of Affective Disorders·O CuretB Scatton
Nov 24, 2004·Journal of Psychiatric Practice·Jess G Fiedorowicz, Karen L Swartz
Feb 24, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Paul E Holtzheimer, Charles B Nemeroff
Mar 4, 2008·Primary Care Companion to the Journal of Clinical Psychiatry·Larry Culpepper, Lawrence J Kovalick
Aug 30, 2008·Neuropsychiatric Disease and Treatment·Pasquale G FrisinaHarriet R Tenenbaum
Jan 1, 1993·Journal of Neural Transmission. General Section·A S Brown, S Gershon
Mar 1, 1992·Italian Journal of Neurological Sciences·G FinaliG L Piccinin
May 7, 1999·Journal of the American Academy of Child and Adolescent Psychiatry·G J EmslieM Ernst
Jan 1, 1991·Acta Neurologica Scandinavica. Supplementum·A J Lees
Jan 1, 1991·Acta Neurologica Scandinavica. Supplementum·H AllainH C Neukirch
Jan 1, 1991·Acta Neurologica Scandinavica. Supplementum·E H Heinonen, R Lammintausta
Jul 1, 1992·Biological Psychiatry·S Kapur, J J Mann
Dec 1, 1994·General Pharmacology·P H Yu
May 1, 2008·The International Journal of Neuroscience·Pasquale G FrisinaNancy S Foldi
Oct 3, 2015·Expert Review of Clinical Pharmacology·Adam M BiedThomas L Schwartz
Nov 18, 2006·Expert Opinion on Pharmacotherapy·Paul E Holtzheimer, Charles B Nemeroff
Dec 14, 2006·Expert Opinion on Pharmacotherapy·Paul J Goodnick
Feb 4, 2016·Expert Opinion on Drug Delivery·Mario A Cristancho, Michael E Thase
May 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·J C Garcia-MoncoM Gomez Beldarrain
May 1, 1993·Medicinal Research Reviews·R M Pinder, J H Wieringa
Sep 7, 2007·Journal of the Neurological Sciences·Daniel D TruongErik Wolters
Jul 27, 2007·European Journal of Pharmacology·Colin DavidsonEverett H Ellinwood
Jul 7, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Chi-Un PaeAshwin A Patkar
Jun 15, 2007·Journal of Affective Disorders·Donald S Robinson, Jay D Amsterdam
Jul 21, 2006·Journal of Clinical Pharmacology·Albert J AzzaroBryan J Campbell
Apr 1, 1990·Acta Neurologica Scandinavica·H Teräväinen
Jan 1, 1989·Acta Neurologica Scandinavica. Supplementum·E H HeinonenU K Rinne
Nov 20, 2003·Biological Psychiatry·Lynn WeckerMary A Pacheco
Jul 15, 2015·CNS Drugs·Daphne Robakis, Stanley Fahn
Sep 8, 2012·International Journal of Pharmaceutics·Dhaval R KalariaYogeshvar N Kalia
Sep 25, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Joanna S FowlerLisa Muench
Nov 3, 2016·Frontiers in Pharmacology·John P M Finberg, Jose M Rabey
Nov 16, 1989·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Aug 29, 1991·The New England Journal of Medicine·W Z PotterH Manji
Nov 1, 1991·Acta Neurologica Scandinavica·M H Hietanen
Oct 1, 1995·Journal of Geriatric Psychiatry and Neurology·D J Knesper

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.